| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/135248505MS1322OA |
| P698 | PubMed publication ID | 16900763 |
| P50 | author | Mar Tintoré | Q41423156 |
| Jordi Rio | Q57064308 | ||
| Xavier Montalban | Q58685888 | ||
| P2093 | author name string | Manuel Comabella | |
| Carlos Nos | |||
| Nieves Téllez | |||
| Eva Julià | |||
| Luís Brieva | |||
| P2860 | cites work | Defining the clinical course of multiple sclerosis: Results of an international survey | Q22241638 |
| Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 | ||
| An Inventory for Measuring Depression | Q26778503 | ||
| Fatigue associated with multiple sclerosis: diagnosis, impact and management | Q28180100 | ||
| Chronic fatigue syndrome: new insights and old ignorance | Q33785889 | ||
| Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid | Q34303859 | ||
| An open study of dehydroepiandrosterone in systemic lupus erythematosus | Q34725009 | ||
| Dissociation of Cortisol and Adrenal Androgen Secretion in Patients with Secondary Adrenal Insufficiency | Q40253308 | ||
| Side effect profile of interferon beta-1b in MS: results of an open label trial | Q40952067 | ||
| Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment | Q42520744 | ||
| Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement--EEG evidence. | Q43607426 | ||
| Fatigue is not associated with raised inflammatory markers in multiple sclerosis | Q43721311 | ||
| Fatigue and proinflammatory cytokine activity in breast cancer survivors | Q44078653 | ||
| Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats | Q44447763 | ||
| Replacement therapy in Addison's disease | Q44670544 | ||
| The relationship between diffuse axonal damage and fatigue in multiple sclerosis | Q44766912 | ||
| Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. | Q44809937 | ||
| Cytokine mRNA expression in patients with multiple sclerosis and fatigue | Q44881825 | ||
| Immunologic abnormalities associated with chronic fatigue syndrome. | Q45951578 | ||
| Effects of exercise on muscle activation and metabolism in multiple sclerosis | Q46318700 | ||
| Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis | Q48686682 | ||
| Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study | Q48695940 | ||
| Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors | Q48723389 | ||
| Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis | Q49048792 | ||
| Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. | Q50930205 | ||
| Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. | Q55033164 | ||
| Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? | Q57601992 | ||
| Primary progressive multiple sclerosis | Q57912056 | ||
| P433 | issue | 4 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 487-494 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
| P1476 | title | Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone | |
| P478 | volume | 12 |
| Q27007478 | 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review |
| Q55357541 | Androgen-Induced Immunosuppression. |
| Q42789516 | Biological outcome measurements for behavioral interventions in multiple sclerosis |
| Q37442056 | Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients |
| Q42905689 | Evaluation of the Persian version of modified fatigue impact scale in Iranian patients with multiple sclerosis |
| Q50063088 | Fatigue as a symptom or comorbidity of neurological diseases |
| Q34021881 | Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment |
| Q28299922 | Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways |
| Q57601977 | Fatigue in multiple sclerosis persists over time |
| Q92857748 | Fatigue, Sleep, and Autoimmune and Related Disorders |
| Q37419043 | Immunosuppression in clinical practice: approaches to individualized therapy |
| Q55347930 | Is there a link between inflammation and fatigue in multiple sclerosis? |
| Q47687936 | Light therapy for multiple sclerosis-associated fatigue: Study protocol for a randomized controlled trial. |
| Q94019542 | Multiple sclerosis |
| Q37785555 | Multiple sclerosis-associated fatigue |
| Q28220405 | Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression |
| Q36780439 | Origin of fatigue in multiple sclerosis: review of the literature |
| Q38978087 | Pathophysiology, assessment and management of multiple sclerosis fatigue: an update |
| Q48126920 | Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation |
| Q28073849 | The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue |
| Q41197337 | The promyelinating properties of androstenediol in gliotoxin-induced demyelination in rat corpus callosum. |
Search more.